Akers Biosciences Signs a Further Independent Sales Representative Organization for Heparin PF4 Rapid Test Covering Additiona...
July 18 2018 - 7:01AM
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio”
or the "Company"), a developer of rapid health information
technologies, announces another agreement with a major Independent
Sales Representative (ISR) organization, adding sales and marketing
coverage for the Company’s rapid test for heparin-induced
thrombocytopenia (HIT) across an additional 12 states.
The agreement with Appleton Medical Services,
based in St. Louis, Missouri, will place Akers Bio’s flagship HIT
test into the hands of a further 14 speciality medical product
sales representatives, focused on implementing solutions into the
clinical pathway.
Appleton Medical Services will target clinical
end-users of, and those able to prescribe, HIT tests, including
surgeons and surgical teams. Their teams will provide sales and
marketing exposure for PIFA Heparin/PF4 Rapid Assay products in
Indiana, Kentucky, Minnesota, Illinois, Wisconsin, Mississippi,
Louisiana, Missouri, Kansas, Iowa, Nebraska and Arkansas; as well
as providing coverage in certain areas of Texas, Wyoming and
Colorado which are not currently represented by existing ISR
partners with coverage in those states.
Since the start of 2018, Akers Bio has developed
sales and marketing coverage through ISRs in 39 of the 50 United
States, covering more than 75 per cent of the country’s total
population.
John J. Gormally, Chief Executive
Officer of Akers Bio, commented: “A key goal for Akers Bio
has been to establish broad Independent Sales Representative
coverage for our primary commercialized test, leveraging the
specialized skills and relevant relationships of our chosen
partners in their respective regions. This is central to the
strategy of raising awareness of the benefits of our rapid heparin
platelet factor 4 antibody test and to influencing the clinical
pathway for the diagnosis of HIT.
As a result of the tremendous efforts of our
sales and marketing team, we are now represented by 55 sales people
from 9 organizations covering 39 states which are home to over
three-quarters of the US population. We fully expect to further
expand this footprint as we focus on driving profitable growth for
our core products.”
About Akers Biosciences,
Inc.
Akers Bio develops, manufactures, and supplies
rapid screening and testing products designed to deliver quicker
and more cost-effective healthcare information to healthcare
providers and consumers. The Company has advanced the science of
diagnostics while responding to major shifts in healthcare through
the development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its
products can be found at www.akersbio.com. Follow us on Twitter
@AkersBio.
Cautionary Note Regarding Forward
Looking Statements
Statements contained herein that are not based
upon current or historical fact are forward-looking in nature and
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements reflect the Company's expectations about
its future operating results, performance and opportunities that
involve substantial risks and uncertainties. Such statements may
include, without limitation, statements with respect to the
Company’s plans, compliance with the requirements of various
regulatory agencies, objectives, projections, expectations and
intentions and other statements identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential” or similar expressions, as they relate to the Company,
its subsidiaries, or its management. These statements are based
upon the current beliefs and expectations of the Company’s
management and are subject to significant risks and uncertainties,
including those detailed in the Company’s filings with the
Securities and Exchange Commission. Actual results, performance,
prospects, and opportunities to may differ materially from those
set forth in, or implied by, the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company’s control). The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
For more information:
Akers Biosciences, Inc.John J. Gormally, Chief
Executive OfficerTel. +1 856 848 8698
Vigo Communications (Global Public Relations)Ben
Simons / Fiona HensonTel. +44 (0)20 7390 0234Email:
akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Sep 2023 to Sep 2024